Global Acute Lymphoblastic Leukemia Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

12/feb/2018 03:22:32 pbi Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Increase in the incidence of acute lymphoblastic leukemia, rise in the R&D activities for the innovation of novel therapies, growing in healthcare expenditure, and advancement in molecular biology and pharmacology for development of novel drugs are anticipated to fuel the acute lymphoblastic leukemia treatment market. In addition, rise in awareness programs for acute lymphoblastic leukemia treatment, and increase in healthcare expenditure are expected propel the growth of acute lymphoblastic leukemia treatment market over the forecast period. However, stringent regulatory policies, high cost of treatment, adverse effects associated with the treatment, and complications with chemotherapy are expected to hinder the growth of acute lymphoblastic leukemia treatment market over the forecast period.

 Global Acute Lymphoblastic Leukemia Treatment Market:

 Acute lymphoblastic leukemia or acute lymphocytic leukemia is a type of leukemia occurs due to the accumulation and overproduction of cancerous white blood cells known as lymphoblasts in the bone marrow. Acute lymphoblastic leukemia may spread to other body organs such as liver, spleen, lymph nodes, and central nervous system among others. Acute lymphoblastic leukemia is most commonly occurs in children and sometimes in children with 2-5 years of age and rarely occurs in old age population. Common signs and symptoms associated with the acute lymphoblastic leukemia include fatigue, fever, frequent infections, bruising, weight loss, joint pains, and swollen lymph glands among others. It can be diagnosed by bone marrow test, blood test, ultrasound, MRI, and CT scans among others.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-acute-lymphoblastic-leukemia-treatment-market/#ulp-4H8Z4LpNMLEuOnnx 

 

 

Acute lymphoblastic leukemia treatment market is segmented on the basis of disease type, treatment type, route of administration, and end users

 

Based on the disease type, acute lymphoblastic leukemia treatment market is segmented into the following:

·         Acute B-lymphoblastic Leukemia

·         Acute T-lymphoblastic Leukemia

·         Others

 

Based on the treatment type, acute lymphoblastic leukemia treatment market is segmented into the following:

·         Chemotherapy

o    Corticosteroids

o    Colony-stimulating Factors

o    Tyrosine Kinase Inhibitors

o    Others

·         Immunotherapy

·         Others

 

Based on the route of administration, acute lymphoblastic leukemia treatment market is segmented into the following:

·         Oral

·         Parenteral

 

Based on the distribution channel, acute lymphoblastic leukemia treatment market is segmented into the following:

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-acute-lymphoblastic-leukemia-treatment-market/#ulp-c654SbFYO64MsOhu

 

 

 

Acute lymphoblastic leukemia treatment market is growing at lucrative rate owing to increase in the prevalence of acute lymphoblastic leukemia prevalence in developing countries due to genetic factors. The rise in R&D activities for the innovation of newer chemotherapy and immunotherapy molecules is anticipated to fuel the acute lymphoblastic leukemia treatment market. Moreover, acquisitions and mergers, collaborations, and product launchings are the key strategies followed by the companies for dominating the acute lymphoblastic leukemia treatment market. For instance, In April 2014, Rare Disease Therapeutics, Inc. received FDA approval for Purixan oral suspension, used in the treatment of acute lymphoblastic leukemia. Moreover, in September 2015, Baxter International Inc. acquired Oncaspar product portfolio from the Sigma-Tau Finanziaria S.p.A. for strengthening its acute lymphoblastic leukemia portfolio.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-acute-lymphoblastic-leukemia-treatment-market/#ulp-14mlyhjMGhVjZqa3

 

 

 

Geographically, acute lymphoblastic leukemia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has a significant growth which is attributed to increase in the prevalence of acute lymphoblastic leukemia (according to estimation of American Cancer Society about 6,590 new cases and 1,430 deaths are observed in U.S.), rise in R&D for innovation of new drugs, and various drugs approved by FDA are fuelling the acute lymphoblastic leukemia treatment market in the region. In Europe, rise in prevalence of acute lymphoblastic leukemia majorly in Russia, Norway, and U.K (according to Cancer Research U.K. 2014, about 758 new cases were observed in U.K.), rise in awareness about the disease treatment, and increase in healthcare expenditure are the factors boosting the acute lymphoblastic leukemia treatment market. However, Asia Pacific has a lucrative growth which is attributed to high prevalence of the disease majorly in Australia.

 

 

Some of the players in acute lymphoblastic leukemia treatment market are Pfizer, Inc. (U.S.), Sigma-Tau Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Genzyme Corporation (U.S.). Talon Therapeutic, Inc. (U.S.), Erytech Pharma (France), Baxter International Inc. (U.S.), Novartis AG (Switzerland), and Rare Disease Therapeutics, Inc. (U.S.) to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-acute-lymphoblastic-leukemia-treatment-market/

 

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl